BioVaxys (BVAXF) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $12.5M

Market Cap: $2.5MFounded: 2019HQ: Vancouver, United States

Sector Ranking#205 in Biologics / Biosimilars

Overview

BioVaxys is a clinical-stage biopharma company focused on harnessing the immune system to combat cancer and infectious diseases. Its strategic acquisition of IMV Inc. transformed the company, providing a validated DPX™ delivery platform and mid-stage clinical assets, most notably the Phase 2B cancer vaccine maveropepimut-S (MVP-S). The company's business model centers on advancing its platform and pipeline to proof-of-concept before out-licensing to larger partners for late-stage development and commercialization.

OncologyInfectious Diseases

Technology Platform

The DPX™ platform is a synthetic lipid-in-oil delivery system with a 'no-release' mechanism that forces active uptake of vaccine payloads by immune cells at the injection site, promoting potent, targeted T-cell responses.

Funding History

2

Total raised:$12.5M

Series A$10MUndisclosedMar 15, 2022

Seed$2.5MUndisclosedJun 15, 2021

Opportunities

The DPX platform's validated ability to induce potent T-cell responses presents a major opportunity in the growing cancer vaccine and next-generation infectious disease vaccine markets.

Positive Phase 2 data across multiple tumor types could attract lucrative partnership deals with large pharma.

Risk Factors

High clinical development risk, significant near-term funding requirements, and intense competition in the immunotherapy space.

As a micro-cap stock, it also faces liquidity and capital market access risks.

Competitive Landscape

Competes with other cancer vaccine developers (e.g., BioNTech, Gritstone) and delivery platform companies (e.g., LNP developers). Key differentiation is the DPX platform's 'no-release' mechanism designed for superior, localized T-cell priming, as evidenced in clinical studies.